96 results
PRE 14A
APTX
Aptinyx Inc.
23 May 23
Preliminary proxy
8:25am
, and the discussions in this proxy statement regarding tax consequences are general in nature.
We have not requested a ruling from the IRS with respect … on page 8 of this proxy statement.
The description of the Dissolution contained in this introductory section is general in nature and is subject
8-K
EX-99.1
hgd80
30 Mar 23
Aptinyx Reports on Fourth Quarter and Full Year 2022 Results and Highlights and Review of Strategic Alternatives
4:15pm
8-K
EX-99.1
eknc hbz1
8 Nov 22
Aptinyx Reports Third Quarter 2022 Financial Results and Recent Highlights
4:15pm
8-K
EX-99.1
addak
25 Aug 22
Aptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson’s Disease and Dementia with Lewy Bodies
11:45am
8-K
EX-99.1
9fl9xmkw32t zr
12 Aug 22
Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Fibromyalgia
7:15am
8-K
EX-99.1
w8j6spiyhtzn8vjcd
4 Aug 22
Aptinyx Reports Second Quarter 2022 Financial Results and Recent Highlights
4:15pm
8-K
EX-99.1
6hksi1cn0
12 May 22
Aptinyx Reports First Quarter 2022 Financial Results and Highlights Recent Clinical Progress
4:16pm
8-K
3aifdc5t b449bb
19 Apr 22
Other Events
7:00am
8-K
EX-99.1
aq221ubdxhccwnlh b2s
7 Apr 22
Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy
7:15am